These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
619 related articles for article (PubMed ID: 26412796)
1. Pathophysiology of Osteonecrosis of the Jaws. Aghaloo T; Hazboun R; Tetradis S Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):489-96. PubMed ID: 26412796 [TBL] [Abstract][Full Text] [Related]
2. Antiresorptives and osteonecrosis of the jaw. Yamashita J; McCauley LK J Evid Based Dent Pract; 2012 Sep; 12(3 Suppl):233-47. PubMed ID: 23040351 [TBL] [Abstract][Full Text] [Related]
3. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors. Dodson TB Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367 [TBL] [Abstract][Full Text] [Related]
4. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)]. Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441 [TBL] [Abstract][Full Text] [Related]
5. [Osteonecrosis of the jaws (ONJ) associated to antiresorptive treatment]. Larsson Wexell C; Kjellman A; Akre O Lakartidningen; 2018 May; 115():. PubMed ID: 29809272 [TBL] [Abstract][Full Text] [Related]
6. Issues with the surgical treatment of antiresorptive agent-related osteonecrosis of the jaws. Kagami H; Inoue M; Kobayashi A; Taguchi A; Li X; Yoshizawa M Oral Dis; 2018 Mar; 24(1-2):52-56. PubMed ID: 29480637 [TBL] [Abstract][Full Text] [Related]
7. Drug-induced osteonecrosis of the jaw: the state of the art. Fassio A; Bertoldo F; Idolazzi L; Viapiana O; Rossini M; Gatti D Reumatismo; 2017 May; 69(1):9-15. PubMed ID: 28535616 [TBL] [Abstract][Full Text] [Related]
8. Antiresorptive drug-related osteonecrosis of the jaw. Uyanne J; Calhoun CC; Le AD Dent Clin North Am; 2014 Apr; 58(2):369-84. PubMed ID: 24655528 [TBL] [Abstract][Full Text] [Related]
9. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. Khan AA; Morrison A; Kendler DL; Rizzoli R; Hanley DA; Felsenberg D; McCauley LK; O'Ryan F; Reid IR; Ruggiero SL; Taguchi A; Tetradis S; Watts NB; Brandi ML; Peters E; Guise T; Eastell R; Cheung AM; Morin SN; Masri B; Cooper C; Morgan SL; Obermayer-Pietsch B; Langdahl BL; Dabagh RA; Davison KS; Sándor GK; Josse RG; Bhandari M; El Rabbany M; Pierroz DD; Sulimani R; Saunders DP; Brown JP; Compston J; J Clin Densitom; 2017; 20(1):8-24. PubMed ID: 27956123 [TBL] [Abstract][Full Text] [Related]
11. Antiresorptive Agent-Related Osteonecrosis of the Jaw (ARONJ): A Twist of Fate in the Bone. Shibahara T Tohoku J Exp Med; 2019 Feb; 247(2):75-86. PubMed ID: 30713280 [TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS. Anastasilakis AD; Pepe J; Napoli N; Palermo A; Magopoulos C; Khan AA; Zillikens MC; Body JJ J Clin Endocrinol Metab; 2022 Apr; 107(5):1441-1460. PubMed ID: 34922381 [TBL] [Abstract][Full Text] [Related]
13. Antiresorptive treatment-associated ONJ. Eleutherakis-Papaiakovou E; Bamias A Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 29063702 [TBL] [Abstract][Full Text] [Related]
14. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE; J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958 [TBL] [Abstract][Full Text] [Related]
15. Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice. Kang B; Cheong S; Chaichanasakul T; Bezouglaia O; Atti E; Dry SM; Pirih FQ; Aghaloo TL; Tetradis S J Bone Miner Res; 2013 Jul; 28(7):1631-40. PubMed ID: 23426919 [TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of Bisphosphonate-associated Osteonecrosis of the Jaw. Fung PL; Nicoletti P; Shen Y; Porter S; Fedele S Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):537-46. PubMed ID: 26299425 [TBL] [Abstract][Full Text] [Related]
17. Bisphosphonate-related osteonecrosis of the jaws - characteristics, risk factors, clinical features, localization and impact on oncological treatment. Otto S; Schreyer C; Hafner S; Mast G; Ehrenfeld M; Stürzenbaum S; Pautke C J Craniomaxillofac Surg; 2012 Jun; 40(4):303-9. PubMed ID: 21676622 [TBL] [Abstract][Full Text] [Related]
18. Medication-related osteonecrosis of the jaw associated with bisphosphonates and denosumab in osteoporosis. Bagan J; Peydró A; Calvo J; Leopoldo M; Jiménez Y; Bagan L Oral Dis; 2016 May; 22(4):324-9. PubMed ID: 26818808 [TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the Jaw in Patients Receiving Bone-Targeted Therapies: An Overview--Part I. Turner B; Drudge-Coates L; Ali S; Pati J; Nargund V; Ali E; Cheng L; Wells P Urol Nurs; 2016; 36(3):111-6, 154. PubMed ID: 27501591 [TBL] [Abstract][Full Text] [Related]
20. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]